Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1916

1.

Irisin in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Anastasilakis AD, Geladari EV, Mantzoros CS.

Metabolism. 2014 Feb;63(2):207-17. doi: 10.1016/j.metabol.2013.09.013.

PMID:
24140091
2.

Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.

Polyzos SA, Kountouras J, Papatheodorou A, Katsiki E, Patsiaoura K, Zafeiriadou E, Papadopoulou E, Zavos C, Terpos E.

Ann Hepatol. 2013 Sep-Oct;12(5):749-57.

3.

Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort.

Kashyap SR, Diab DL, Baker AR, Yerian L, Bajaj H, Gray-McGuire C, Schauer PR, Gupta M, Feldstein AE, Hazen SL, Stein CM.

Obesity (Silver Spring). 2009 Sep;17(9):1696-701. doi: 10.1038/oby.2009.89.

4.

Serum homocysteine levels in patients with nonalcoholic fatty liver disease.

Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G, Zavos C, Gavalas E, Katsinelos P, Mane V, Slavakis A.

Ann Hepatol. 2012 Jan-Feb;11(1):68-76.

5.

Adipokines and C-reactive protein in relation to bone mineralization in pediatric nonalcoholic fatty liver disease.

Pacifico L, Bezzi M, Lombardo CV, Romaggioli S, Ferraro F, Bascetta S, Chiesa C.

World J Gastroenterol. 2013 Jul 7;19(25):4007-14. doi: 10.3748/wjg.v19.i25.4007.

6.

Serum chemerin and vaspin in non-alcoholic fatty liver disease.

Kukla M, Zwirska-Korczala K, Hartleb M, Waluga M, Chwist A, Kajor M, Ciupinska-Kajor M, Berdowska A, Wozniak-Grygiel E, Buldak R.

Scand J Gastroenterol. 2010;45(2):235-42. doi: 10.3109/00365520903443852.

PMID:
20095887
7.

Association between serum irisin levels and non-alcoholic fatty liver disease in health screen examinees.

Choi ES, Kim MK, Song MK, Kim JM, Kim ES, Chung WJ, Park KS, Cho KB, Hwang JS, Jang BK.

PLoS One. 2014 Oct 24;9(10):e110680. doi: 10.1371/journal.pone.0110680.

8.

Adipokines in a group of Mexican patients with nonalcoholic steatohepatitis.

Muñoz LE, Cordero P, Torres L, Sauceda AY, Flores JP, Segura JJ.

Ann Hepatol. 2009 Apr-Jun;8(2):123-8.

PMID:
19502655
9.

Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease.

Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S.

Nutr Clin Pract. 2013 Feb;28(1):101-11. doi: 10.1177/0884533612454884.

PMID:
23042833
10.

Serum concentration of adiponectin, leptin and resistin in obese children with non-alcoholic fatty liver disease.

Lebensztejn DM, Wojtkowska M, Skiba E, Werpachowska I, Tobolczyk J, Kaczmarski M.

Adv Med Sci. 2009;54(2):177-82. doi: 10.2478/v10039-009-0047-y.

PMID:
20022856
11.

Long-term effects of aerobic plus resistance training on the adipokines and neuropeptides in nonalcoholic fatty liver disease obese adolescents.

de Piano A, de Mello MT, Sanches Pde L, da Silva PL, Campos RM, Carnier J, Corgosinho F, Foschini D, Masquio DL, Tock L, Oyama LM, do Nascimento CM, Tufik S, Dâmaso AR.

Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1313-24.

PMID:
22932160
12.

Liver enzymes but not free fatty acid levels predict markers of insulin sensitivity in overweight and obese, nondiabetic adults.

Gray B, Muhlhausler BS, Davies PS, Vitetta L.

Nutr Res. 2013 Oct;33(10):781-8. doi: 10.1016/j.nutres.2013.07.019.

PMID:
24074735
13.

Noninvasive clinical model for the diagnosis of nonalcoholic steatohepatitis in overweight and morbidly obese patients undergoing bariatric surgery.

Pirvulescu I, Gheorghe L, Csiki I, Becheanu G, Dumbravă M, Fica S, Martin S, Sarbu A, Gheorghe C, Diculescu M, Copăescu C.

Chirurgia (Bucur). 2012 Nov-Dec;107(6):772-9.

14.

Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.

Malloy VL, Perrone CE, Mattocks DA, Ables GP, Caliendo NS, Orentreich DS, Orentreich N.

Metabolism. 2013 Nov;62(11):1651-61. doi: 10.1016/j.metabol.2013.06.012.

PMID:
23928105
15.

Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology.

Jung KY, Cho SY, Kim HJ, Kim SB, Song IH.

J Clin Gastroenterol. 2014 Nov-Dec;48(10):883-8. doi: 10.1097/MCG.0000000000000065.

PMID:
24440936
16.

Serum adipocyte fatty acid-binding protein levels are associated with nonalcoholic fatty liver disease in type 2 diabetic patients.

Koh JH, Shin YG, Nam SM, Lee MY, Chung CH, Shin JY.

Diabetes Care. 2009 Jan;32(1):147-52. doi: 10.2337/dc08-1379.

17.

Plasma adiponectin is decreased in nonalcoholic fatty liver disease.

Pagano C, Soardo G, Esposito W, Fallo F, Basan L, Donnini D, Federspil G, Sechi LA, Vettor R.

Eur J Endocrinol. 2005 Jan;152(1):113-8.

18.

Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH).

Krawczyk K, Szczesniak P, Kumor A, Jasinska A, Omulecka A, Pietruczuk M, Orszulak-Michalak D, Sporny S, Malecka-Panas E.

J Physiol Pharmacol. 2009 Oct;60 Suppl 3:71-5.

19.

Chemerin correlates with markers for fatty liver in morbidly obese patients and strongly decreases after weight loss induced by bariatric surgery.

Sell H, Divoux A, Poitou C, Basdevant A, Bouillot JL, Bedossa P, Tordjman J, Eckel J, Clément K.

J Clin Endocrinol Metab. 2010 Jun;95(6):2892-6. doi: 10.1210/jc.2009-2374.

PMID:
20375212
20.

Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis?

Cengiz C, Ardicoglu Y, Bulut S, Boyacioglu S.

Eur J Gastroenterol Hepatol. 2010 Jul;22(7):813-9. doi: 10.1097/MEG.0b013e32833283cb.

PMID:
19820404

Supplemental Content

Support Center